EDAP TMS SA to Announce Fourth Quarter 2021 Financial Results on Wednesday, March 30, 2022

Rhea-AI Summary

EDAP TMS SA will release its financial results for Q4 2021 on March 30, 2022, after market close. The company will host a conference call on March 31, 2022, at 8:30 am ET, featuring key executives including CEO Marc Oczachowski and CFO François Dietsch. EDAP is a leader in therapeutic ultrasound, offering products such as the Focal One® and ExactVu™ for prostate cancer treatment. The call will provide insights into the company's performance and future outlook, key points for investors to consider.

Positive

• EDAP continues to lead in the therapeutic ultrasound market, indicating strong market presence.
• The introduction of ExactVu™ positions EDAP uniquely in the prostate cancer treatment segment.

Negative

• None.

Company to host conference call and webcast on Thursday, March 31, at 8:30 am ET

LYON, France, March 21, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter ended December 31, 2021 after the markets close on Wednesday, March 30, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am ET on Thursday, March 31, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, March 31^st @ 8:30am Eastern Time
Domestic:                877-451-6152
International:           201-389-0879
Passcode:                13727107
Webcast:                 https://viavid.webcasts.com/starthere.jsp?ei=1529371&tp_key=b54f335485

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

CONTACTS:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com

 

FAQ

What are the financial results for EDAP TMS SA for Q4 2021?

EDAP TMS SA will announce its Q4 2021 financial results on March 30, 2022.

When is the conference call for EDAP TMS SA's Q4 results?

The conference call is scheduled for March 31, 2022, at 8:30 am ET.

Who will participate in the EDAP TMS SA conference call?

Key executives including Marc Oczachowski and François Dietsch will participate in the call.

What products does EDAP TMS SA offer for prostate cancer treatment?

EDAP offers the Focal One® and ExactVu™ devices for prostate cancer treatment.